MA32081B1 - Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer - Google Patents

Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer

Info

Publication number
MA32081B1
MA32081B1 MA33089A MA33089A MA32081B1 MA 32081 B1 MA32081 B1 MA 32081B1 MA 33089 A MA33089 A MA 33089A MA 33089 A MA33089 A MA 33089A MA 32081 B1 MA32081 B1 MA 32081B1
Authority
MA
Morocco
Prior art keywords
quinazolines
dialkoxyquinazoline
surprisingly
class
treating cancer
Prior art date
Application number
MA33089A
Other languages
Arabic (ar)
English (en)
Inventor
Prasad Ramanadham Jyothi
Kali Satya Bhujanga Rao Adibhatla
Rao Bollepalli Nageshwara
Chowdary Nannapaneni Venkaiah
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MA32081B1 publication Critical patent/MA32081B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compte tenu du potentiel important offert par la classe de composés formés par les quinazolines, la synthèse et le criblage d'un grand nombre de nouvelles entités chimiques à nouvelles caractéristiques structurales a été entreprise. De façon surprenante et inattendue, il a été prouvé que les quinazolines ayant un groupe 3- éthynylanilino en position 4 et des groupes alcoxy substitués de façon spécifique dans les positions 6 et 7 confèrent propriétés antiprolifératives très améliorées et spéciales par rapport à d'autres éléments importants de la classe de médicaments formée par les quinazolines. Egalement, de façon surprenante, les composés de cette invention sont bien moins toxiques et le profil d'innocuité est extrêmement avantageux pour les applications thérapeutiques. Les nouvelles entités chimiques décrites dans cette invention sont représentées par la structure générale (i) et n'ont jamais été synthétisées ou étudiées pour leurs avantages thérapeutiques et leur profil d'innocuité. Le composé (i) est le nrc-2694, de structure (a).
MA33089A 2008-01-18 2010-08-13 Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer MA32081B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000036 WO2009090661A1 (fr) 2008-01-18 2008-01-18 Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer

Publications (1)

Publication Number Publication Date
MA32081B1 true MA32081B1 (fr) 2011-02-01

Family

ID=39769348

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33089A MA32081B1 (fr) 2008-01-18 2010-08-13 Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer

Country Status (27)

Country Link
US (5) US8143250B2 (fr)
EP (2) EP3012251B1 (fr)
JP (1) JP2011509995A (fr)
KR (2) KR101640161B1 (fr)
CN (1) CN101918374A (fr)
AP (1) AP2886A (fr)
AU (1) AU2008347940A1 (fr)
BR (1) BRPI0822012A2 (fr)
CA (1) CA2711737C (fr)
CY (1) CY1118193T1 (fr)
DK (2) DK3012251T3 (fr)
EA (1) EA018514B1 (fr)
ES (2) ES2593321T3 (fr)
HR (1) HRP20161522T1 (fr)
HU (1) HUE030640T2 (fr)
IL (1) IL207046A (fr)
LT (1) LT2229369T (fr)
MA (1) MA32081B1 (fr)
MX (1) MX2010007852A (fr)
NZ (1) NZ586946A (fr)
PL (1) PL2229369T3 (fr)
PT (1) PT2229369T (fr)
SG (1) SG187490A1 (fr)
SI (1) SI2229369T1 (fr)
UA (1) UA101010C2 (fr)
WO (1) WO2009090661A1 (fr)
ZA (1) ZA201005116B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918374A (zh) * 2008-01-18 2010-12-15 纳特科制药有限公司 用于治疗癌症相关病症的6.7-二烷氧基喹唑啉衍生物
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
CN101857618B (zh) * 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
CN103874696B (zh) * 2011-10-12 2015-06-03 苏州韬略生物科技有限公司 作为激酶抑制剂的喹唑啉衍生物及其使用方法
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
US9546179B2 (en) * 2011-12-20 2017-01-17 Wei Qian Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof
CA2868302A1 (fr) 2012-03-23 2013-09-26 Dennis M. Brown Compositions et procedes d'amelioration du benefice therapeutique de l'indirubine et de ses analogues y compris du mesoindigo
AU2014353006B2 (en) * 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
ES2899145T3 (es) * 2017-04-15 2022-03-10 Natco Pharma Ltd Un proceso mejorado para la preparación de diclorhidrato de N-(3-etinilfenil)-7-metoxi-6-(3-morfolinopropoxi)quinazolin-4-amina
CN111499577A (zh) * 2019-01-30 2020-08-07 华东师范大学 邻二苯基取代五元含氮芳杂环类类化合物及其应用
AU2022291015A1 (en) 2021-06-10 2023-12-21 Natco Pharma Limited Egfr inhibitor for the treatment of head and neck cancer
CN115518071B (zh) * 2021-06-24 2024-03-19 中国人民解放军联勤保障部队第九〇一医院 一种化合物在制备抗食管癌的药物中的应用
WO2024121861A1 (fr) * 2022-12-08 2024-06-13 Natco Pharma Limited Inhibiteur d'egfr pour traiter le cancer de la tête et du cou

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US690221A (en) 1901-06-20 1901-12-31 Frederik Christian Viggo Arp Stand for cycles.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
WO2005070909A1 (fr) 2004-01-22 2005-08-04 Natco Pharma Limited Procede ameliore de preparation de gefitinib
WO2006090413A1 (fr) 2005-02-23 2006-08-31 Natco Pharma Limited Nouvelle forme cristalline de gefitinib et son procede de preparation
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
WO2007060691A2 (fr) 2005-11-23 2007-05-31 Natco Pharma Limited Nouveau procede pour la preparation d'erlotinib
CN101918374A (zh) * 2008-01-18 2010-12-15 纳特科制药有限公司 用于治疗癌症相关病症的6.7-二烷氧基喹唑啉衍生物

Also Published As

Publication number Publication date
ES2642159T3 (es) 2017-11-15
PL2229369T3 (pl) 2017-01-31
US20150141421A1 (en) 2015-05-21
UA101010C2 (ru) 2013-02-25
CY1118193T1 (el) 2017-06-28
US8921362B2 (en) 2014-12-30
AP2010005357A0 (en) 2010-08-31
EA018514B1 (ru) 2013-08-30
KR101762306B1 (ko) 2017-07-27
DK3012251T3 (en) 2017-10-09
EP3012251B1 (fr) 2017-08-30
AP2886A (en) 2014-05-31
BRPI0822012A2 (pt) 2015-07-21
HRP20161522T1 (hr) 2017-02-10
DK2229369T3 (en) 2016-12-12
NZ586946A (en) 2012-06-29
WO2009090661A1 (fr) 2009-07-23
KR20160086969A (ko) 2016-07-20
KR20100121468A (ko) 2010-11-17
US9481655B2 (en) 2016-11-01
ZA201005116B (en) 2011-03-30
WO2009090661A9 (fr) 2010-06-17
EP3012251A1 (fr) 2016-04-27
PT2229369T (pt) 2016-11-24
ES2593321T3 (es) 2016-12-07
US20110034459A1 (en) 2011-02-10
CA2711737C (fr) 2015-03-31
HUE030640T2 (en) 2017-06-28
AU2008347940A1 (en) 2009-07-23
LT2229369T (lt) 2016-09-26
CN101918374A (zh) 2010-12-15
EA201001173A1 (ru) 2011-04-29
SI2229369T1 (sl) 2016-11-30
EP2229369B1 (fr) 2016-08-17
EP2229369A1 (fr) 2010-09-22
JP2011509995A (ja) 2011-03-31
KR101640161B1 (ko) 2016-07-15
US20110039844A1 (en) 2011-02-17
US20170079983A1 (en) 2017-03-23
CA2711737A1 (fr) 2009-07-23
US8143250B2 (en) 2012-03-27
IL207046A0 (en) 2010-12-30
IL207046A (en) 2015-09-24
US20190201408A1 (en) 2019-07-04
SG187490A1 (en) 2013-02-28
MX2010007852A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
MA32081B1 (fr) Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer
MA32120B1 (fr) Nouveaux composes chimiques
Ali et al. Synthesis of isatin thiosemicarbazones derivatives: In vitro anti-cancer, DNA binding and cleavage activities
Ali et al. Synthesis of copper (II) complexes of isatin thiosemicarbazone derivatives: In vitro anti-cancer, DNA binding, and cleavage activities
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
JP4652054B2 (ja) アルツハイマー病を治療するための、二重結合部位アセチルコリンエステラーゼ阻害剤
MA27725A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
EA200501895A1 (ru) Соединения амфетамина с пониженной способностью вызывать злоупотребление ими
TW200633982A (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
MA30289B1 (fr) Dérivés d'amines
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
HK1049333A1 (zh) 以环状琥珀酸酯代替内酰胺，作为制造Aβ蛋白质的抑制剂
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
FI924397A0 (fi) Substituerade pyrimidiner.
MA38069A1 (fr) Composés hétéroaromatiques utilisés comme ligands de la dopamine d1
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
Zawadzka et al. Highly selective inhibition of butyrylcholinesterase by a novel melatonin–tacrine heterodimers
EA200800975A1 (ru) ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ
MXPA02001813A (es) Hidroxialcanoilaminolactamas y estructuras relacionas como inhibidores de la produccion de la proteina abeta.
Xu et al. Multifunctional 5, 6-dimethoxybenzo [d] isothiazol-3 (2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer’s disease
MA29566B1 (fr) Composes chimiques
CY1107362T1 (el) Παραγωγα ιμιδαζολυλιου χρησιμα ως συνδετες υποδοχεων ισταμινης h3